Millennium Management’s AIM ImmunoTech AIM Stock Holding History

Millennium Management’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-182	Closed	-$6K	–	7492
2022 Q4	$6K	Sell	182 -112	-38%	-$5.2K	﹤0.01%	6291
2022 Q3	$17K	Buy	+294	New	+$20.6K	﹤0.01%	6516
2022 Q2	–	Sell	-130	Closed	-$14K	–	7945
2022 Q1	$14K	Hold	130	–	–	﹤0.01%	6702
2021 Q4	$12K	Sell	130 -414	-76%	-$64K	﹤0.01%	6644
2021 Q3	$110K	Buy	+544	New	+$110K	﹤0.01%	6399
2020 Q4	–	Sell	-177	Closed	-$38	–	5884
2020 Q3	$38	Buy	+177	New	+$44.2K	﹤0.01%	4317
2020 Q2	–	Sell	-1,946	Closed	-$498K	–	4902
2020 Q1	$498K	Buy	+1,946	New	+$305K	﹤0.01%	2882
2016 Q3	–	Hold	0	–	-$2K	–	3951
2016 Q2	–	Hold	0	–	–	–	3125
2016 Q1	–	Hold	0	–	–	–	3209
2014 Q2	–	Sell	-5	Closed	-$102K	–	4335
2014 Q1	$102K	Buy	+5	New	+$106K	﹤0.01%	3296

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Millennium Management's AIM Position: Q1 2023 in Review

Millennium Management sold out of AIM ImmunoTech (AIM) in Q1 2023, closing a stake of 182 shares — an estimated $6K sold.

Millennium Management first reported a position in AIM in Q1 2014 and held it in 8 quarters. The position peaked at $498K in Q1 2020. 31 funds tracked by Wall St. Rank hold AIM as of Q1 2023.

Millennium Management reported no remaining AIM ImmunoTech position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 182 AIM ImmunoTech shares in Q1 2023, an estimated $6K.
Millennium Management first reported a position in AIM ImmunoTech in Q1 2014 and held it in 8 quarters.
Millennium Management's AIM ImmunoTech position peaked at $498K in Q1 2020.
31 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.